Page 1

Hong Kong Exchanges and Clearing Limited , The Stock Exchange of Hong Kong Limited and Singapore Exchange Securities Trading Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . CS 康哲 药业 CHINA MEDICAL SYSTEM CHINA MEDICAL SYSTEM HOLDINGS LIMITED 康哲 藥業 控股 有限公司 * ( Incorporated in the Cayman Islands with Limited Liability ) ( Hong Kong Stock Code : 867 ) ( Singapore Stock Code : 8A8 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 The board of Directors ( the " Board " ) of China Medical System Holdings Limited ( the “ Company ” ) is pleased to announce the unaudited condensed consolidated results of the Company and its subsidiaries ( the " Group " or " CMS " ) for the six months ended 30 June 2026 ( the " Reporting Period ” ) . Financial Highlights Turnover up 12.5 % to RMB4,500.7 million ( H1 2025 : RMB4,002.0 million ) ; in the case that all medicines were directly sold by the Group , turnover up 14.4 % to RMB5,341.4 million ( H1 2025 : RMB4,669.6 million ) Gross profit up 11.4 % to RMB3,220.6 million ( H1 2025 : RMB2,891.9 million ) ; in the case that all medicines were directly sold by the Group , gross profit up 11.5 % to RMB3,212.3 million ( H1 2025 : RMB2,881.7 million ) Profit for the period up 4.3 % to RMB971.5 million ( H1 2025 : RMB931.5 million ) Basic earnings per share up 4.7 % to RMB0.4075 ( H1 2025 : RMB0.3892 ) As at 30 June 2026 , the Group's bank balances and cash amounted to RMB2,571.9 million Declared interim dividend per share of RMB0.1634 ( H1 2025 : RMB0.1555 ) , representing an increase of 5.1 % and demonstrating the commitment to rewarding shareholders for their trust . In addition , during the Reporting Period , the Group executed share repurchases based on the strong confidence in its long - term value , and approximately 6.4 million shares had been repurchased at an aggregate consideration of approximately HK $ 67.9 million . * For Identification Only